900030ICURE Aid for Start Ups Cohort 3 - Pertinax LtdClosedStudyInnovate UKPertinax is a novel formulation of the antimicrobial drug chlorhexidine (CHX) for use in dentistry and healthcare. CHX is in widespread use but its efficacy and applications are limited by its short duration of activity, which is typically less than 12 hours. This limitation is overcome by Pertinax technology, which extends the duration of action to weeks, months or years. The company has confirmed market demand and has understood market size and opportunity. The development of a robust and scaleable manufacturing process is now the principal barrier to commercial success. The company believes that having established a manufacturing process it could a) supply its technology in bulk form to customers to generate early income, b) complete one or more commercial partnership deals currently in negotiation and c) raise commercial finance for development purposes.